Autobio Diagnostics Co., Ltd. (SHA:603658)
China · Delayed Price · Currency is CNY 36.18
-0.09 (-0.25%)
At close: Feb 13, 2026
Autobio Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,136 | 4,389 | 4,368 | 4,366 | 3,686 | 2,898 |
Other Revenue | 81.98 | 81.98 | 76.05 | 75.76 | 79.82 | 80.1 |
| 4,218 | 4,471 | 4,444 | 4,442 | 3,766 | 2,978 | |
Revenue Growth (YoY) | -7.92% | 0.62% | 0.05% | 17.94% | 26.45% | 11.15% |
Cost of Revenue | 1,522 | 1,582 | 1,612 | 1,844 | 1,545 | 1,216 |
Gross Profit | 2,697 | 2,889 | 2,832 | 2,597 | 2,221 | 1,762 |
Selling, General & Admin | 1,012 | 953.05 | 920.21 | 857.11 | 757.02 | 589.91 |
Research & Development | 613.59 | 731.93 | 656.13 | 568.48 | 480.96 | 342.8 |
Other Operating Expenses | 16.72 | -3.25 | 28.05 | 28.24 | 13.73 | 22.75 |
Operating Expenses | 1,667 | 1,737 | 1,626 | 1,471 | 1,267 | 981.61 |
Operating Income | 1,030 | 1,152 | 1,206 | 1,126 | 954.28 | 780.48 |
Interest Expense | -17.21 | -22.28 | -24.54 | -21.23 | -12.68 | -29.05 |
Interest & Investment Income | 133.31 | 112.84 | 144.76 | 135.09 | 116.43 | 61.8 |
Currency Exchange Gain (Loss) | 0.63 | 0.63 | 1.19 | 7.47 | -9.65 | -2.76 |
Other Non Operating Income (Expenses) | 17.75 | -2.08 | -2.9 | -5.18 | 0.77 | -15.78 |
EBT Excluding Unusual Items | 1,164 | 1,241 | 1,325 | 1,242 | 1,049 | 794.69 |
Gain (Loss) on Sale of Investments | -9.75 | 3.61 | 0.58 | - | 0.03 | 0.09 |
Gain (Loss) on Sale of Assets | -11.03 | -12.2 | -2.78 | -1.72 | -1.17 | -1.13 |
Asset Writedown | -58.7 | -52.75 | - | - | - | - |
Other Unusual Items | 109.07 | 109.07 | 39.95 | 53.06 | 17.54 | 50.88 |
Pretax Income | 1,194 | 1,289 | 1,363 | 1,294 | 1,066 | 844.53 |
Income Tax Expense | 91.43 | 89.82 | 138.41 | 105.03 | 85.69 | 87.44 |
Earnings From Continuing Operations | 1,103 | 1,199 | 1,224 | 1,189 | 979.86 | 757.09 |
Minority Interest in Earnings | -4.73 | -4.78 | -6.69 | -21.25 | -6.19 | -9.3 |
Net Income | 1,098 | 1,194 | 1,217 | 1,167 | 973.66 | 747.79 |
Net Income to Common | 1,098 | 1,194 | 1,217 | 1,167 | 973.66 | 747.79 |
Net Income Growth | -13.74% | -1.89% | 4.28% | 19.90% | 30.20% | -3.41% |
Shares Outstanding (Basic) | 572 | 577 | 580 | 584 | 587 | 558 |
Shares Outstanding (Diluted) | 572 | 577 | 580 | 584 | 587 | 558 |
Shares Change (YoY) | -1.08% | -0.47% | -0.68% | -0.48% | 5.10% | 2.03% |
EPS (Basic) | 1.92 | 2.07 | 2.10 | 2.00 | 1.66 | 1.34 |
EPS (Diluted) | 1.92 | 2.07 | 2.10 | 2.00 | 1.66 | 1.34 |
EPS Growth | -12.80% | -1.43% | 5.00% | 20.48% | 23.88% | -5.33% |
Free Cash Flow | 617.3 | 644.88 | 569.44 | 620.1 | 395.39 | -120.67 |
Free Cash Flow Per Share | 1.08 | 1.12 | 0.98 | 1.06 | 0.67 | -0.22 |
Dividend Per Share | 1.260 | 1.260 | 1.052 | 0.800 | 0.750 | 0.654 |
Dividend Growth | 19.76% | 19.76% | 31.51% | 6.67% | 14.71% | -5.56% |
Gross Margin | 63.92% | 64.61% | 63.73% | 58.47% | 58.98% | 59.17% |
Operating Margin | 24.41% | 25.77% | 27.15% | 25.36% | 25.34% | 26.21% |
Profit Margin | 26.02% | 26.71% | 27.40% | 26.28% | 25.86% | 25.11% |
Free Cash Flow Margin | 14.63% | 14.42% | 12.81% | 13.96% | 10.50% | -4.05% |
EBITDA | 1,515 | 1,616 | 1,642 | 1,544 | 1,340 | 1,082 |
EBITDA Margin | 35.92% | 36.15% | 36.96% | 34.76% | 35.59% | 36.33% |
D&A For EBITDA | 485.28 | 464.2 | 436.1 | 417.56 | 385.93 | 301.56 |
EBIT | 1,030 | 1,152 | 1,206 | 1,126 | 954.28 | 780.48 |
EBIT Margin | 24.41% | 25.77% | 27.15% | 25.36% | 25.34% | 26.21% |
Effective Tax Rate | 7.66% | 6.97% | 10.16% | 8.12% | 8.04% | 10.35% |
Revenue as Reported | 4,218 | 4,471 | 4,444 | 4,442 | 3,766 | 2,978 |
Advertising Expenses | - | 54.35 | 55.79 | 41.4 | 45.1 | 32.03 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.